A carregar...
Publicação
Reavaliação de Tecnologias de Saúde: estado da arte em Portugal e na Europa
| Nome: | Descrição: | Tamanho: | Formato: | |
|---|---|---|---|---|
| 1.82 MB | Adobe PDF |
Orientador(es)
Resumo(s)
O Governo português continua, ano após ano, a reduzir a despesa alocada à saúde. Deste valor, cerca de um quarto do mesmo encontra-se alocado à comparticipação e aquisição de tecnologias de saúde.
Por outro lado, os doentes exigem que com menos se faça mais. Posto isto, há que rentabilizar ao máximo este orçamento.
Até ao presente ano de dois mil e dezasseis, a concessão de uma comparticipação a uma dada tecnologia de saúde, ou a possibilidade desta ser adquirida a nível hospitalar, era ad eternum. No entanto, o passar dos anos associado ao progresso científico que tem ocorrido faz com que, progressivamente, sejam introduzidas no mercado tecnologias de saúde com resultados significativamente melhores às já disponíveis. Paralelamente, certos medicamentos e dispositivos médicos, quando expostos a ambientes não controlados, acabam por não demonstrar efetividades semelhantes à eficácia evidenciada.
Dados estes e outros fatores, o novo Sistema Nacional de Avaliação de Tecnologias de Saúde introduziu a possibilidade de reavaliar medicamentos e dispositivos médicos, permitindo uma melhor utilização dos recursos públicos em saúde através da redução de desperdícios e premiação de inovações relevantes, ou seja, excluindo de comparticipação todas as tecnologias de saúde que não apresentem valor terapêutico acrescentado e alocando tal valor para financiar tecnologias de saúde inovadoras.
O objetivo deste trabalho passa por analisar o ponto de situação do processo de reavaliação de tecnologias de saúde em Portugal – que à data de apresentação deste trabalho se iniciou apenas para um grupo de medicamentos (análogos da DPP4) e estando também a ser considerada a possibilidade de reavaliação de alguns medicamentos biológicos e a reanálise de preços de associações fixas para o VIH/SIDA –, comparando-o com o de outros países europeus, e estimando alguns outcomes que poderão surgir advir do mesmo.
Portuguese Government continues to reduce, year after year, the budget allocated for health. From this value, around one quarter of it it’s used for reimbursements and acquisitions of health technologies. On the other hand, patients demand the National Health System to do more with less resources. Since this, it is essential to monetize this budget. Until two thousand and sixteen, the authorization of a reimbursement to a certain health technology, or the possibility for its acquisition by the National Health System, was ad eternum. However, as time goes by and with the scientific progression that is occurring, it is possible to assess progressively the introduction of health technologies with better results that the previous ones. At the same time, certain drugs and medical devices, when exposed to non-controlled environments, don’t show the same effectiveness compared to its efficiency in clinical trials. Due to this and several other factors, the brand new national system for health technology assessment introduced the possibility of doing a revaluation of medicines and medical devices , allowing a better used of public resources in health not only with the reduction of wastes but also rewarding relevant innovations, which means that every health technologies that are not showing added therapeutic value will lose its reimbursements and that this budget can be allocated to finance innovative alternatives. The main goal of this work is analyzing the point of situation of the revaluation system in Portugal – which has only begun for one single group of medicines (DPP4’s analogs), being also considered the possibility of revaluate some biologic drugs and the reanalyze of HIV association’s prices – comparing it with other European countries and estimating the possible outcomes.
Portuguese Government continues to reduce, year after year, the budget allocated for health. From this value, around one quarter of it it’s used for reimbursements and acquisitions of health technologies. On the other hand, patients demand the National Health System to do more with less resources. Since this, it is essential to monetize this budget. Until two thousand and sixteen, the authorization of a reimbursement to a certain health technology, or the possibility for its acquisition by the National Health System, was ad eternum. However, as time goes by and with the scientific progression that is occurring, it is possible to assess progressively the introduction of health technologies with better results that the previous ones. At the same time, certain drugs and medical devices, when exposed to non-controlled environments, don’t show the same effectiveness compared to its efficiency in clinical trials. Due to this and several other factors, the brand new national system for health technology assessment introduced the possibility of doing a revaluation of medicines and medical devices , allowing a better used of public resources in health not only with the reduction of wastes but also rewarding relevant innovations, which means that every health technologies that are not showing added therapeutic value will lose its reimbursements and that this budget can be allocated to finance innovative alternatives. The main goal of this work is analyzing the point of situation of the revaluation system in Portugal – which has only begun for one single group of medicines (DPP4’s analogs), being also considered the possibility of revaluate some biologic drugs and the reanalyze of HIV association’s prices – comparing it with other European countries and estimating the possible outcomes.
Descrição
Trabalho Final de Mestrado Integrado, Ciências Farmacêuticas, Universidade de Lisboa, Faculdade de Farmácia, 2016
Palavras-chave
Reavaliação ATS Comparticipação SNS Acesso ao Mercado Mestrado Integrado - 2016